The milestone BRILLIANCE trial tested the efficacy and safety of EDIT-101, which is a CRISPR-targeted therapy for the CEP290 gene mutation for Leber Congenital Amaurosis 10 (LCA10). Here, CEP290 is linked to Leber congenital amaurosis.